Edwards Lifesciences: Outperforming in Healthcare
Update: 2025-12-02
Description
Edwards Lifesciences, a leading medical technology company, has seen significant growth, reaching a 52-week high of $87.40. Despite a brief dip after Q3 results, the stock quickly recovered, outperforming the iShares U.S. Medical Devices ETF. Analysts maintain a Moderate Buy rating, suggesting a potential 10% upside.
The Daily News Now! — Every city. Every story. AI-powered.
Hosted on Acast. See acast.com/privacy for more information.
Comments
In Channel
Download from Google Play
Download from App Store
United States00:00
00:00
1.0x
